Urinary excretion of codeine, ethylmorphine, and their metabolites: Relation to the CYP2D6 activity

Therapeutic Drug Monitoring

Volumn 19, Issue 6, 1997, Pages 643-649

  Hedenmalm, Karin ^a   Sundgren, Margit ^a   Granberg, Kerstin ^a   Spigset, Olav ^a   Dahlqvist, Rune ^a  

^a UMEÅ UNIVERSITY HOSPITAL   (Sweden)

Author keywords

Codeine; Ethylmorphine; Metabolites; Polymorphism; Screening analyses; Urinary excretion

Indexed keywords

COCILLANA ETYFIN; CODEINE; CODEINE PHOSPHATE; DEBRISOQUINE 4 HYDROXYLASE; DEXTROMETHORPHAN; DRUG METABOLITE; ETHYLMORPHINE; MORPHINE; NORCODEINE; UNCLASSIFIED DRUG;

ADULT; ARTICLE; CLINICAL TRIAL; DRUG EXCRETION; DRUG SCREENING; FEMALE; GAS CHROMATOGRAPHY; HUMAN; HUMAN EXPERIMENT; IMMUNOASSAY; MALE; MASS SPECTROMETRY; NORMAL HUMAN; ORAL DRUG ADMINISTRATION; PRIORITY JOURNAL; URINARY EXCRETION;

ADULT; ANALGESICS, OPIOID; CODEINE; CYTOCHROME P-450 CYP2D6; ETHYLMORPHINE; FEMALE; HUMANS; MALE; METABOLIC CLEARANCE RATE; PHENOTYPE;

EID: 0031456765     PISSN: 01634356     EISSN: None     Source Type: Journal    
DOI: 10.1097/00007691-199712000-00007     Document Type: Article

References (16)

1. Chen ZR, Somogyi AA, Bochner F. Polymorphic O-demethylation of codeine. Lancet 1988;ii:914-5.
2. Yue QY, Svensson J-O, Alm C, Sjöqvist F, Säwe J. Codeine O-demethylation cosegregates with polymorphic debrisoquine hydroxylation. Br J Clin Pharmacol 1989;28:639-45.
3. Mortimer Ö, Persson K, Ladona MG. Polymorphic formation of morphine from codeine in poor and extensive metabolizers of dextromethorphan: relationship to the presence of immunoidentified cytochrome P-450IID1. Clin Pharmacol Ther 1990;47:27-35.
4. Rane A, Modiri AR, Gerdin E. Ethylmorphine O-deethylation Cosegregates with the debrisoquin genetic metabolic polymorphism. Clin Pharmacol Ther 1992;52:257-64.
5. Liu Z, Mortimer Ö, Smith CA, Wolf CR, Rane A. Evidence for a role of cytochrome P450 2D6 and 3A4 in ethylmorphine metabolism. Br J Clin Pharmacol 1995;39:77-80.
6. Ladona MG, Lindström B, Thyr C, Dun-Ren P, Rane A. Differential foetal development of the O- and N-demethylation of codeine and dextromethorphan in man. Br J Clin Pharmacol 1991; 32:295-302.
7. Spigset O, Granberg K, Hägg S, Norström Å, Dahlqvist R. Relationship between fluvoxamine pharmacokinetics and CYP2D6/ CYP2C19 phenotype polymorphisms. Eur J Clin Pharmacol 1997;52:129-33.
8. Lin Z, Lafolie P, Beck O. Evaluation of analytical procedures for urinary codeine and morphine measurements. J Anal Toxicol 1994; 18:129-33.
9. Hasselström J, Säwe J. Morphine kinetics and metabolism in man; enterohepatic cycling and relative contribution of metabolites to active opioid concentrations. Clin Pharmacokinet 1993;24: 344-54.
10. Dutt MC, Siaw-Teck Lo D, Kheng Ng DL, Woo S-O. Gas chromatographic study of the urinary codeine-to-morphine ratios in controlled codeine consumption and in mass screening of opiate drugs. J Chromatogr 1983;267:117-24.
11. Cone EJ, Welch P, Paul BD, Mitchell JM. Forensic drug testing for opiates, III: Urinary excretion rates of morphine and codeine following codeine administration. J Anal Toxicol 1991;15:161-6.
12. Ripel Å, Christophersen AS, Bjørnebøe, Mørland J. Morphine formation after intake of ethylmorphine. Pharmacol Toxicol 1992;70: 228-9.
13. Yong LH, Ng TL. The human urinary excretion pattern of morphine and codeine following the consumption of morphine, opium, codeine and heroin. Bull Narcot 1977;29:45-74.
14. Aasmundstad TA, Xu BQ, Johansson I, et al. Biotransformation and pharmacokinetics of ethylmorphine after a single oral dose. Br J Clin Pharmacol 1995;39:611-20.
15. Cone EJ, Paul BD, Mitchell JM. Forensic drug testing for opiates, V: Urine testing for heroin, morphine, and codeine with commercial opiate immunoassays. J Anal Toxicol 1993;17:156-64.
16. Yue QY, Hasselström J, Svensson JO, Säwe J. Pharmacokinetics of codeine and its metabolites in caucasian healthy volunteers: comparisons between extensive and poor hydroxylators of debrisoquine. Br J Clin Pharmacol 1991;31:635-42.